Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 2;9(1):71.
doi: 10.1186/s13643-020-01332-7.

Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review

Maryam Ahmadzadeh  1   2   3 , Gregory J Christie  1   2   3 , Theodore D Cosco  4   5 , Sylvain Moreno  6   7   8
Affiliations

Neuroimaging and analytical methods for studying the pathways from mild cognitive impairment to Alzheimer's disease: protocol for a rapid systematic review

Maryam Ahmadzadeh et al. Syst Rev. .

Abstract

Background: Alzheimer's disease (AD) is a neurodegenerative disorder commonly associated with deficits of cognition and changes in behavior. Mild cognitive impairment (MCI) is the prodromal stage of AD that is defined by slight cognitive decline. Not all with MCI progress to AD dementia. Thus, the accurate prediction of progression to Alzheimer's, particularly in the stage of MCI could potentially offer developing treatments to delay or prevent the transition process. The objective of the present study is to investigate the most recent neuroimaging procedures in the domain of prediction of transition from MCI to AD dementia for clinical applications and to systematically discuss the machine learning techniques used for the prediction of MCI conversion.

Methods: Electronic databases including PubMed, SCOPUS, and Web of Science will be searched from January 1, 2017, to the date of search commencement to provide a rapid review of the most recent studies that have investigated the prediction of conversion from MCI to Alzheimer's using neuroimaging modalities in randomized trial or observational studies. Two reviewers will screen full texts of included papers using predefined eligibility criteria. Studies will be included if addressed research on AD dementia and MCI, explained the results in a way that would be able to report the performance measures such as the accuracy, sensitivity, and specificity. Only studies addressed Alzheimer's type of dementia and its early-stage MCI using neuroimaging modalities will be included. We will exclude other forms of dementia such as vascular dementia, frontotemporal dementia, and Parkinson's disease. The risk of bias in individual studies will be appraised using an appropriate tool. If feasible, we will conduct a random effects meta-analysis. Sensitivity analyses will be conducted to explore the potential sources of heterogeneity.

Discussion: The information gathered in our study will establish the extent of the evidence underlying the prediction of conversion to AD dementia from its early stage and will provide a rigorous and updated synthesis of neuroimaging modalities allied with the data analysis techniques used to measure the brain changes during the conversion process.

Systematic review registration: PROSPERO,CRD42019133402.

Keywords: Alzheimer; Conversion; Data analysis; Machine learning; Mild cognitive impairment; Modality; Neuroimaging; Prediction; Systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

References

    1. Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s & Dementia. 2013;9:63–75. doi: 10.1016/j.jalz.2012.11.007. - DOI - PubMed
    1. Alzheimer’s Association 2018 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia. 2018;14:367–429. doi: 10.1016/j.jalz.2018.02.001. - DOI - PubMed
    1. Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: definition, natural history, and diagnostic criteria. Alzheimer’s & Dementia. 2016;12:292–323. doi: 10.1016/j.jalz.2016.02.002. - DOI - PMC - PubMed
    1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & Dementia. 2011;7:280–292. doi: 10.1016/j.jalz.2011.03.003. - DOI - PMC - PubMed
    1. Pereira T, Cardoso S, Silva D, de Mendonça A, Guerreiro M, Madeira SC. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer’s disease: a feature selection ensemble combining stability and predictability. BMC Medical Informatics and Decision Making [Internet]. 2018 [cited 2019 Aug 11];18. Available from: https://bmcmedinformdecismak.biomedcentral.com/articles/10.1186/s12911-0.... - DOI - PMC - PubMed

Publication types